This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Health Canada Expands Indications Of Abilify® (aripiprazole), To Be The First Add-On Treatment For Major Depressive Disorder (MDD)

MONTREAL, June 6, 2013 /CNW/ - Abilify® (aripiprazole) has received an additional approval from Health Canada as an adjunct, or add-on, treatment to antidepressants for the treatment of major depressive disorder (MDD) in adults who had an inadequate response to prior antidepressant treatments during the current episode. When used with an antidepressant, Abilify has been shown to improve the symptoms of adults living with MDD who had an inadequate response to at least two trials with antidepressants during the current episode. It is the first add-on treatment for MDD to be approved in Canada.

The Health Canada approval is based on results from three six-week double-blind, randomized, placebo-controlled, multicentre studies (n=1088). The results from all three studies demonstrated significant improvement in depressive symptoms in adult patients with a primary diagnosis of MDD who had experienced an inadequate response * to monotherapy with two or more antidepressants. In fact, significant improvements in depression symptoms were seen in the second week of add-on treatment with Abilify, when compared to the control.

"Even if a patient responds according to set standardized scores, they often still experience problematic residual symptoms, which can prevent a fully functional return to everyday activities.  Furthermore, these residual symptoms are a strong predictor of relapse within a relatively short timeframe," says Dr. Pierre Blier, Head of the Mood Disorders Research Unit of the Royal Ottawa Hospital and Government of Canada Chair in Psychopharmacology. "In the Canadian CANMAT treatment guidelines for the treatment of MDD - as in others around the world - Abilify is recommended for add-on to antidepressants. This new indication gives physicians and their patients with MDD an option when relief cannot be achieved with antidepressants alone."

MDD is a serious mental illness characterized by one or more major depressive episodes. The primary symptom of MDD is a sad, despairing mood, which is present most days and lasts most of the day, continues for more than two weeks, and impairs the individual's functioning at work, at school and / or in social relationships. MDD is a complex mood disorder, which is caused by several factors including genetic disposition, personality, stress, and brain chemistry. It can develop at any age, with the average age of onset in the mid-twenties.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs